Anti-müllerian hormone and premature ovarian insufficiency

Anti-Müllerian Hormone: Biology, Role in Ovarian Function and Clinical Significance

Volumn , Issue , 2016, Pages 197-207

  Jacquesson, Laetitia ^a,b   Bachelot, Anne ^a,b   Touraine, Philippe ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Center of Rare Growth Hormone Disorders   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85051876475     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (42)

1. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas. 2008 Sep-Oct;61(1-2):4-16.
2. Beck-Peccoz P, Persani L. Premature ovarian failure. Orphanet J Rare Dis 2006;1:9.
3. Goswami D, Conway GS. Premature ovarian failure. Horm Res. 2007;68(4):196-202.
4. Kim TJ, Anasti JN, Flack MR, Kimzey LM, Defensor RA, Nelson LM. Routine endocrine screening for patients with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol. 1997 May;89:777-9.
5. Taylor AE, Adams JM, Mulder JE, Martin KA, Sluss PM, Crowley WF Jr. A randomized, controlled trial of estradiol replacement therapy in women with hypergonadotropic amenorrhea. J Clin Endocrinol Metab. 1996 Oct;81(10):3615-21.
6. Nelson LM, Anasti JN, Kimzey LM, Defensor RA, Lipetz KJ, White BJ, Shawker TH, Merino MJ. Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure. J Clin Endocrinol Metab. 1994 Nov;79(5):1470-5.
7. Bidet M, Bachelot A, Bissauge E, Golmard JL, Gricourt S, Dulon J, Coussieu C, Badachi Y, Touraine P. Resumption of ovarian function and pregnancies in 358 patients with premature ovarian failure. J Clin Endocrinol Metab 2011;96:3864-72.
8. Massagué J. The transforming growth factor-beta family. Annu Rev Cell Biol. 1990;6:597-641. Review.
9. Rajpert-De Meyts E, Jørgensen N, Graem N, Müller J, Cate RL, Skakkebaek NE. Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J Clin Endocrinol Metab. 1999 Oct;84(10):3836-44.
10. Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev. 2009 Aug;30(5):465-93.
11. Broer SL, Broekmans FJ, Laven JS, Fauser BC. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014.
12. Lambalk CB, van Disseldorp J, de Koning CH, Broekmans FJ. Testing ovarian reserve to predict age at menopause. Maturitas. 2009 Aug 20;63(4):280-91.
13. Vainio S, Heikkilä M, Kispert A, Chin N, McMahon AP. Female development in mammals is regulated by Wnt-4 signalling. Nature. 1999 Feb 4;397(6718):405-9.
14. Prunskaite-Hyyryläinen R, Shan J, Railo A, Heinonen KM, Miinalainen I, Yan W, Shen B, Perreault C, Vainio SJ. Wnt4, a pleiotropic signal for controlling cell polarity, basement membrane integrity, and antimüllerian hormone expression during oocyte maturation in the female follicle. FASEB J. 2014 Apr,28(4):1568-81.
15. Uhlenhaut NH, Treier M. Foxl2 function in ovarian development. Mol Genet Metab. 2006 Jul;88(3):225-34.
16. Pisarska MD, Barlow G, Kuo FT. Minireview: roles of the forkhead transcription factor FOXL2 in granulosa cell biology and pathology. Endocrinology. 2011 Apr,152(4):1199-208.
17. Uda M, Ottolenghi C, Crisponi L, Garcia JE, Deiana M, Kimber W, Forabosco A,Cao A, Schlessinger D, Pilia G. Foxl2 disruption causes mouse ovarian failure by pervasive blockage of follicle development. Hum Mol Genet. 2004 Jun 1;13(11):1171-81.
18. Park M, Suh DS, Lee K, Bae J. Positive cross talk between FOXL2 and antimüllerian hormone regulates ovarian reserve. Fertil Steril. 2014 Sep;102(3):847-855.
19. Elvin JA, Yan C, Matzuk MM. Oocyte-expressed TGF-beta superfamily members in female fertility. Mol Cell Endocrinol. 2000 Jan 25;159(1-2):1-5.
20. Galloway SM, McNatty KP, Cambridge LM, Laitinen MP, Juengel JL, Jokiranta TS, McLaren RJ, Luiro K, Dodds KG, Montgomery GW, Beattie AE, Davis GH, Ritvos O. Mutations in an oocyte-derived growth factor gene (BMP15) cause increased ovulation rate and infertility in a dosage-sensitive manner. Nat Genet. 2000 Jul;25(3):279-83.
21. Estienne A, Pierre A, di Clemente N, Picard JY, Jarrier P, Mansanet C,Monniaux D, Fabre S. Anti-Müllerian hormone regulation by the bone morphogenetic proteins in the sheep ovary: deciphering a direct regulatory pathway. Endocrinology. 2015 Jan;156(1):301-13.
22. Behringer RR, Finegold MJ, Cate RL. Müllerian-inhibiting substance function during mammalian sexual development. Cell. 1994 Nov 4;79(3):415-25.
23. Durlinger AL, Kramer P, Karels B, de Jong FH, Uilenbroek JT, Grootegoed JA,Themmen AP. Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology. 1999 Dec;140(12):5789-96.
24. Visser JA, Durlinger AL, Peters IJ, van den Heuvel ER,Rose UM, Kramer P, de Jong FH, Themmen AP. Increased oocyte degeneration and follicular atresia during the estrous cycle in anti-Müllerian hormone null mice. Endocrinology. 2007 May;148(5):2301-8.
25. Nilsson E, Rogers N, Skinner MK. Actions of anti-Müllerian hormone on the ovarian transcriptome to inhibit primordial to primary follicle transition. Reproduction. 2007 Aug;134(2):209-21.
26. Carlsson IB, Scott JE, Visser JA, Ritvos O, Themmen AP, Hovatta O. Anti-Müllerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Hum Reprod. 2006 Sep;21(9):2223-7.
27. Durlinger AL, Visser JA, Themmen AP. Regulation of ovarian function: the role of anti-Müllerian hormone. Reproduction. 2002 Nov;124(5):601-9. Review.
28. Visser JA, Themmen AP. Role of anti-Müllerian hormone and bone morphogenetic proteins in the regulation of FSH sensitivity. Mol Cell Endocrinol. 2014 Jan 25;382(1):460-5.
29. Knauff EA, Eijkemans MJ, Lambalk CB, ten Kate-Booij MJ, Hoek A, Beerendonk CC,Laven JS, and al; Dutch Premature Ovarian Failure Consortium. Anti-Müllerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J Clin Endocrinol Metab. 2009 Mar;94(3):786-92.
30. Bachelot A, Rouxel A, Massin N, Dulon J, Courtillot C, Matuchansky C, Badachi Y, Fortin A, Paniel B, Lecuru F, Lefrère-Belda MA, Constancis E, Thibault E, Meduri G, Guiochon-Mantel A, Misrahi M, Kuttenn F, Touraine P; POF-GIS Study Group. Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure. Eur J Endocrinol 2009;161:179-187.
31. Gruson D, Homsak E. Measurement of anti-Müllerian hormone: Performances of a new ultrasensitive immunoassay. Clin Biochem. 2015 Jan 6.
32. Méduri G, Massin N, Guibourdenche J, Bachelot A, Fiori O, Kuttenn F, Misrahi M, Touraine P. Serum anti-Müllerian hormone expression in women with premature ovarian failure. Hum Reprod. 2007 Jan;22(1):117-23.
33. Van Beek RD, van den Heuvel-Eibrink MM, Laven JS, de Jong FH, Themmen AP,Hakvoort-Cammel FG, van den Bos C, van den Berg H, Pieters R, de Muinck Keizer-Schrama SM. Anti-Müllerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J Clin Endocrinol Metab. 2007 Oct;92(10):3869-74.
34. Bath LE, Wallace WH, Shaw MP, Fitzpatrick C, Anderson RA. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Müllerian hormone, inhibin B and ovarian ultrasound. Hum Reprod. 2003 Nov;18(11):2368-74.
35. Charpentier AM, Chong AL, Gingras-Hill G, Ahmed S, Cigsar C, Gupta AA,Greenblatt E, Hodgson DC. Anti-Müllerian hormone screening to assess ovarian reserve among female survivors of childhood cancer. J Cancer Surviv. 2014 Dec;8(4):548-54.
36. Partridge AH, Ruddy KJ, Gelber S, Schapira L, Abusief M, Meyer M, Ginsburg E. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril. 2010 Jul;94(2):638-44.
37. Marder W, McCune WJ, Wang L, Wing JJ, Fisseha S, McConnell DS, Christman GM, Somers EC. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. Gynecol Endocrinol. 2012 Aug;28(8):624-7.
38. Morel N, Bachelot A, Chakhtoura Z, Ghillani-Dalbin P, Amoura Z, Galicier L, Aumaitre O, Piette JC, Pourrat J, Boutin D, Sacre K, Kahn JE, Duhaut P, Farge D, Francès C, Guettrot Imbert G, Harlé JR, Lambotte O, Le Guern V, Sène D, Trad S,Vidal E, Sarrot-Reynauld F, Gompel A, Tanguy ML, Touraine P, Lacorte JM, Costedoat-Chalumeau N; PLUS group. Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab. 2013 Sep;98(9):3785-92.
39. Decanter C, Peigne M, Mailliez A, Morschhauser F, Dassonneville A, Dewailly D,Pigny P. Toward a better follow-up of ovarian recovery in young women after chemotherapy with a hypersensitive antimüllerian hormone assay. Fertil Steril. 2014 Aug;102(2):483-7.
40. Dunlop CE, Anderson RA. Uses of anti-Müllerian hormone (AMH) measurement before and after cancer treatment in women. Maturitas. 2014 Dec 18.
41. Imbert R, Moffa F, Tsepelidis S, Simon P, Delbaere A,Devreker F, Dechene J, Ferster A, Veys I, Fastrez M, Englert Y, Demeestere I. Safety and usefulness of cryopreservation of ovarian tissue to preserve fertility: a 12-year rétrospective analysis. Hum Reprod. 2014 Sep;29(9):1931-40.
42. Margolskee A, Selgrade JF. A lifelong model for the female reproductive cycle with an antimüllerian hormone treatment to delay menopause. J Theor Biol. 2013 Jun 7;326:21-35.